Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4435918 | 0.82 | ALOX5 (0.53) | ALOX5ACACBLMNAL3MBTL1HDAC3 | |
| SCHEMBL19329926 | 0.80 | HDAC3 (0.53) | LMNAL3MBTL1HDAC3HDAC1HDAC2 | |
| SCHEMBL22362709 | 0.76 | POLB (0.49) | ALOX5ACACBLMNAL3MBTL1 | |
| SCHEMBL20425136 | 0.75 | LMNA (0.56) | ALOX5ACACBLMNAL3MBTL1MAOB | |
| SCHEMBL6190389 | 0.75 | LMNA (0.58) | ALOX5LMNAL3MBTL1MAOB | |
| SCHEMBL20425199 | 0.75 | NR4A1 (0.53) | ALOX5ACACBLMNAMAOBFFAR1 | |
| SCHEMBL22362711 | 0.75 | BCHE (0.53) | ALOX5ALDH1A1 | |
| SCHEMBL20835322 | 0.75 | BCHE (0.53) | ALOX5ALDH1A1 | |
| SCHEMBL20835321 | 0.75 | BCHE (0.53) | ALOX5ALDH1A1 | |
| SCHEMBL232540 | 0.74 | LMNA (0.59) | ALOX5LMNAL3MBTL1ALDH1A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119196-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119196-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | SLC5A2, SLC5A1, SLC2A2 | ALOX5 4351/4885ACACB 650/4885LMNA 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.